Striate re-certified under new European medical device regs
Filed with ASX · · 3 pages · English
Earlier from Orthocell
- Orthocell receives A$3.17m R&D tax incentive refund
- Orthocell commences nerve repair study
- Leading US-based nerve surgeons appointed to advisory board
- Half Yearly Report and Accounts
- Appendix 4C - Quarterly
Later from Orthocell
- UWA Royalty Entitlement Exchanged for Shares in Orthocell
- Successful OrthoATI clinical trial
- Remplir Expansion Continues with Singapore Application
- Strategic Placement to Raise $3.5 million
- Appendix 4D & Half-Year Financial Statements
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell